Genome‐wide screening identifies novel genes and biological processes implicated in cisplatin resistance

Abstract

Cisplatin‐based chemotherapeutic regimens are frequently used for treatments of solid tumors. However, tumor cells may have inherent or acquired cisplatin resistance, and the underlying mechanisms are largely unknown. We performed genome‐wide screening of genes implicated in cisplatin resistance in A375 human melanoma cells. A substantial fraction of genes whose disruptions cause cisplatin sensitivity or resistance overlap with those whose disruptions lead to increased or decreased cell growth, respectively. Protein translation, mitochondrial respiratory chain complex assembly, signal recognition particle‐dependent cotranslational protein targeting to membrane, and mRNA catabolic processes are the top biologic processes responsible for cisplatin sensitivity. In contrast, proteasome‐mediated ubiquitin‐dependent protein catabolic process, negative regulations of cellular catabolic process, and regulation of cellular protein localization are the top biologic processes responsible for cisplatin resistance. ZNRF3, a ubiquitin ligase known to be a target and negative feedback regulator of Wnt–β‐catenin signaling, enhances cisplatin resistance in normal and melanoma cells independently of β‐catenin. Ariadne‐1 homolog (ARIH1), another ubiquitin ligase, also enhances cisplatin resistance in normal and melanoma cells. By regulating ARIH1, neurofibromin 2, a tumor suppressor, enhances cisplatin resistance in melanoma but not normal cells. Our results shed new lights on cisplatin resistance mechanisms and may be useful for development of cisplatin‐related treatment strategies.—Ko, T., Li, S. Genome‐wide screening identifies novel genes and biological processes implicated in cisplatin resistance. FASEB J. 33, 7143–7154 (2019). http://www.fasebj.org

An Immune-Related Gene Pairs Signature Predicts Overall Survival in Melanoma

“…These pathways are well-known critical factors that affect tumor metastasis. [30][31][32][33] Our ndings suggested that a high-risk score correlates with up-regulation of keratinization and pigment phenotype-related pathways, consistent with the above knowledge. These results suggest the important role of the IRGPI signature in tumor invasion in melanoma patients.…”

Metallodrugs are unique: opportunities and challenges of discovery and development

“…233 Both negative and positive selection genome-wide screens have identied pathways involved in cisplatin resistance and cisplatin sensitivity in human melanoma cells. 234 A combination study with cisplatin and the folate antimetabolite pemetrexed demonstrated that loss of WEE1 sensitises cells to this treatment regime and is a potential therapeutic target. 235 4.4.2 RNAi screening.…”

Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance

“…The genome-wide CRISPR loss-of-function screen also identified genes taking part in cisplatin resistance in melanoma [104]. In this study, the A375 melanoma cell line was combined with the very first CRISPR library (GeCKO.v2) that targets 99.4% of all human genes.…”